Vanguard Group’s OncoSec Medical Incorporated ONCS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-57,488
| Closed | -$148K | – | 4645 |
|
|
2023
Q1 | $148K | Buy |
+57,488
| New | +$114K | ﹤0.01% | 4363 |
|
|
2022
Q4 | – | Sell |
-32,613
| Closed | -$350K | – | 4636 |
|
|
2022
Q3 | $350K | Sell |
32,613
-638
| -2% | -$9.59K | ﹤0.01% | 4307 |
|
|
2022
Q2 | $543K | Hold |
33,251
| – | – | ﹤0.01% | 4273 |
|
|
2022
Q1 | $842K | Hold |
33,251
| – | – | ﹤0.01% | 4264 |
|
|
2021
Q4 | $702K | Sell |
33,251
-1,591
| -5% | -$53.8K | ﹤0.01% | 4361 |
|
|
2021
Q3 | $1.63M | Buy |
34,842
+3,557
| +11% | +$180K | ﹤0.01% | 4122 |
|
|
2021
Q2 | $1.94M | Sell |
31,285
-8,241
| -21% | -$748K | ﹤0.01% | 3970 |
|
|
2021
Q1 | $4.15M | Buy |
39,526
+18,139
| +85% | +$2.48M | ﹤0.01% | 3625 |
|
|
2020
Q4 | $3.04M | Buy |
21,387
+12,622
| +144% | +$1.35M | ﹤0.01% | 3552 |
|
|
2020
Q3 | $652K | Buy |
8,765
+3,249
| +59% | +$253K | ﹤0.01% | 3759 |
|
|
2020
Q2 | $248K | Sell |
5,516
-232
| -4% | -$9.87K | ﹤0.01% | 3895 |
|
|
2020
Q1 | $160K | Sell |
5,748
-240
| -4% | -$8.96K | ﹤0.01% | 3891 |
|
|
2019
Q4 | $238K | Hold |
5,988
| – | – | ﹤0.01% | 3921 |
|
|
2019
Q3 | $259K | Sell |
5,988
-1,950
| -25% | -$91.5K | ﹤0.01% | 3920 |
|
|
2019
Q2 | $442K | Buy |
7,938
+3,702
| +87% | +$356K | ﹤0.01% | 3848 |
|
|
2019
Q1 | $519K | Sell |
4,236
-2
| -0% | -$273 | ﹤0.01% | 3758 |
|
|
2018
Q4 | $596K | Sell |
4,238
-4,663
| -52% | -$1.17M | ﹤0.01% | 3700 |
|
|
2018
Q3 | $2.74M | Buy |
8,901
+30
| +0.3% | +$9.22K | ﹤0.01% | 3428 |
|
|
2018
Q2 | $2.69M | Buy |
8,871
+154
| +2% | +$54K | ﹤0.01% | 3411 |
|
|
2018
Q1 | $3.6M | Buy |
8,717
+5,137
| +143% | +$2.11M | ﹤0.01% | 3271 |
|
|
2017
Q4 | $1.28M | Buy |
3,580
+1,496
| +72% | +$524K | ﹤0.01% | 3547 |
|
|
2017
Q3 | $439K | Buy |
2,084
+22
| +1% | +$4.9K | ﹤0.01% | 3780 |
|
|
2017
Q2 | $540K | Sell |
2,062
-502
| -20% | -$123K | ﹤0.01% | 3712 |
|
|
2017
Q1 | $722K | Buy |
2,564
+656
| +34% | +$191K | ﹤0.01% | 3668 |
|
|
2016
Q4 | $516K | Sell |
1,908
-103
| -5% | -$35.4K | ﹤0.01% | 3730 |
|
|
2016
Q3 | $757K | Buy |
2,011
+56
| +3% | +$21.4K | ﹤0.01% | 3647 |
|
|
2016
Q2 | $705K | Buy |
1,955
+60
| +3% | +$25.3K | ﹤0.01% | 3704 |
|
|
2016
Q1 | $1.06M | Buy |
1,895
+54
| +3% | +$23K | ﹤0.01% | 3580 |
|
|
2015
Q4 | $960K | Buy |
1,841
+128
| +7% | +$96.3K | ﹤0.01% | 3643 |
|
|
2015
Q3 | $1.94M | Buy |
+1,713
| New | +$2.25M | ﹤0.01% | 3390 |
|
Vanguard Group's ONCS Position: Q2 2023 in Review
Vanguard Group sold out of OncoSec Medical Incorporated (ONCS) in Q2 2023, closing a stake of 57,488 shares — an estimated $148K sold.
Vanguard Group first reported a position in ONCS in Q3 2015 and held it in 30 quarters. The position peaked at $4.15M in Q1 2021. 0 funds tracked by Wall St. Rank hold ONCS as of Q2 2023.
- Vanguard Group reported no remaining OncoSec Medical Incorporated position as of Q2 2023 after selling out during the quarter.
- Vanguard Group sold 57,488 OncoSec Medical Incorporated shares in Q2 2023, an estimated $148K.
- Vanguard Group first reported a position in OncoSec Medical Incorporated in Q3 2015 and held it in 30 quarters.
- Vanguard Group's OncoSec Medical Incorporated position peaked at $4.15M in Q1 2021.
- 0 funds tracked by Wall St. Rank held OncoSec Medical Incorporated as of Q2 2023.
Based on Vanguard Group's 13F filing for Q2 2023, filed 14 Aug 2023.